Vanda Pharmaceuticals Inc. Expected to Earn FY2017 Earnings of ($0.53) Per Share (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Investment analysts at Jefferies Group lowered their FY2017 earnings per share estimates for shares of Vanda Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will earn ($0.53) per share for the year, down from their previous estimate of ($0.52). Jefferies Group has a “Buy” rating and a $21.00 price target on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.19) EPS, FY2018 earnings at ($0.34) EPS, FY2019 earnings at $1.37 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.71 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same period last year, the company posted $0.01 earnings per share. The business’s quarterly revenue was up 16.7% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. Expected to Earn FY2017 Earnings of ($0.53) Per Share (VNDA)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/13/vanda-pharmaceuticals-inc-expected-to-earn-fy2017-earnings-of-0-53-per-share-vnda.html.
VNDA has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Vanda Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $21.29.
Vanda Pharmaceuticals (VNDA) opened at 16.35 on Wednesday. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.99. The firm has a 50 day moving average of $17.47 and a 200-day moving average of $15.63. The company’s market capitalization is $733.43 million.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Vanda Pharmaceuticals by 7.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after acquiring an additional 186,548 shares during the period. Point72 Asset Management L.P. lifted its stake in Vanda Pharmaceuticals by 1,544.3% during the 1st quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock valued at $34,783,000 after acquiring an additional 2,333,400 shares during the period. Macquarie Group Ltd. lifted its stake in Vanda Pharmaceuticals by 8.8% during the 2nd quarter. Macquarie Group Ltd. now owns 1,703,559 shares of the biopharmaceutical company’s stock valued at $27,768,000 after acquiring an additional 138,278 shares during the period. State Street Corp lifted its stake in Vanda Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock valued at $26,380,000 after acquiring an additional 46,299 shares during the period. Finally, FMR LLC lifted its stake in Vanda Pharmaceuticals by 60.7% during the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after acquiring an additional 604,900 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.